IP Library Granted Patent US 7,179,901
Granted Patent B2
US 7,179,901 · App. 10/311,388 · Granted Feb 20, 2007

Renal regulatory elements and methods of use thereof

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,179,901
App. No.
10/311,388
Granted
Feb 20, 2007
Kind
B2
Abstract

Disclosed are cis-acting regulatory elements from a KIM-1 gene. The elements can be used to direct the expression of operably linked sequences in renal tissue.

Claims (17)

1. An isolated DNA comprising the nucleotide sequence of SEQ ID NO:3.

2. The DNA of claim 1 , wherein said DNA comprises SEQ ID NO:2.

3. A vector comprising the DNA of claim 1 .

4. An isolated cell comprising the vector of claim 3 .

5. The DNA of claim 1 , wherein said DNA is operably linked to a sequence encoding a KIM-1 antisense nucleic acid.

6. The DNA of claim 1 , wherein the DNA is operably linked to at least one polypeptide-encoding sequence.

7. The DNA of claim 6 , wherein said polypeptide-encoding sequence encodes a KIM-1 polypeptide.

8. The DNA of claim 7 , wherein said KIM-1 polypeptide comprises the amino acid sequence of a human KIM-1 polypeptide.

9. The DNA of claim 6 , wherein said polypeptide-encoding sequence does not encode a KIM-1 polypeptide.

10. The DNA of claim 6 , wherein said polypeptide-encoding sequence encodes a therapeutic polypeptide.

11. The DNA of claim 6 , wherein said polypeptide is selected from the group consisting of a cell survival-promoting factor, a cell growth-promoting factor, a wound-healing factor, an anti-fibrotic factor, an apoptosis-inhibiting factor, an anti-inflammatory factor, a terminal differentiation-promoting factor, a cell growth-inhibiting factor, an intravascular-volume restoration factor, a chelating agent, an alkylating agent, an angiotensin-converting enzyme-inhibiting factor, erythropoietin, a cytokine, a receptor, an anticoagulant, an enzyme, a hormone, an antibody, and a renal structural protein.

12. The DNA of claim 6 , wherein said polypeptide is selected from the group consisting of an insulin growth factor (IGF), an epidermal growth factor (EGF), a fibroblast growth factor (FGF), a transforming growth factor beta (TGF β) Type II receptor, a hepatocyte growth factor (HGF), and an endothelial cell adhesion molecule ICAM-1.

13. A method of directing expression of a recombinant polypeptide, said method comprising:

a) providing a cell comprising the DNA of claim 6 ; and

b) culturing said cell under conditions that allow for the expression of said polypeptide;

thereby directing expression of said polypeptide.

14. The method of claim 13 , wherein said cell is a renal cell.

Assignments (4)
CHANGE OF NAME Recorded May 4, 2015
From: BIOGEN IDEC MA INC.
To: BIOGEN MA INC.
Reel/Frame 035571/0926 →
EXECUTIVE ORDER 9424, CONFIRMATORY LICENSE Recorded Aug 6, 2008
From: GENERAL HOSPITAL CORPORATION DBA MASS
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 021343/0871 →
CHANGE OF NAME Recorded Dec 13, 2006
From: BIOGEN, INC.
To: BIOGEN IDEC MA INC.
Reel/Frame 018625/0154 →
CHANGE OF NAME Recorded Apr 15, 2004
From: BIOGEN IDEC MA, INC.
To: BIOGEN IDEC MA INC.
Reel/Frame 014520/0982 →